TICKERNERD
Menu
QSIQSIHealthcare · Medical Devices

QSI Stock Forecast: Quantum-Si, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$1.22
−4.69% on the day

The 3 Wall Street analysts covering Quantum-Si, Inc. hold a median 12-month price target of $1.9 — +55.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 36 of 100 as at 8 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$267.0M
Ticker Nerd rank
36 / 100
Median analyst target
$1.90
Analysts covering
3
Revenue$344K−41.8% y/y
Operating income−$25.6M
Net income−$23.5M
Free cash flow−$18.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−14.7%
1M
+60.5%
YTD
+10.9%
1Y
−31.1%
From 52W high
−53.6%
From 52W low
+73.8%
$0.70
$2.63
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

QSI stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Quantum-Si, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
36 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
79
Size
64
Issuance
63
Accruals
58
Revisions
52
Momentum
29
Value
24
Quality
17
Volatility
14

Growth (79): Sales and profits are climbing, and climbing faster than before.

Volatility (14): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

QSI stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on QSI, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$1.00$2.00$3.00$4.00Jan 26Apr 26Jul 26Oct 26QSIHigh $3.95Median $1.90Low $1.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says3 analysts
2 Buy1 Hold0 Sell
Low $1.00Median $1.90High $3.95

The green dot is the last close — the median target sits +55.7% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
29 Sept 2026HC Wainwright & Co.ReiteratesBuy$4.00
5 Mar 2026Canaccord GenuityMaintainsHold$1.50 → $1.00
5 Mar 2026Canaccord GenuityMaintainsHold—
22 Dec 2025Canaccord GenuityMaintainsHold—
27 Oct 2025Canaccord GenuityMaintainsHold—
9 Sept 2025Canaccord GenuityMaintainsHold—
19 May 2025HC Wainwright & Co.ReiteratesBuy—
7 Feb 2025Alliance Global PartnersInitiatesBuy—
14 Jan 2025HC Wainwright & Co.ReiteratesBuy—
21 Nov 2024HC Wainwright & Co.MaintainsBuy—
13 Nov 2024Canaccord GenuityMaintainsHold—
13 Nov 2024HC Wainwright & Co.ReiteratesBuy—
10 May 2024HC Wainwright & Co.ReiteratesBuy—
1 Mar 2024HC Wainwright & Co.MaintainsBuy—
8 Dec 2023HC Wainwright & Co.InitiatesBuy—
25 Sept 2023Canaccord GenuityDowngradeHold—
20 Oct 2021Canaccord GenuityInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. QSI appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

QSI vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, Quantum-Si, Inc. returned −31.1% against +16.2% for the S&P 500, dividends included.

QSI vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120140160Jan 26Apr 26Jul 26Oct 26QSIS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

QSI analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Quantum-Si, Inc. (QSI) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−2.4×

Cheaper than 86% of US stocks

Price / sales
164.3×

Cheaper than 3% of US stocks

Price / book
1.5×

Cheaper than 54% of US stocks

EV / EBITDA
−1.8×

Cheaper than 72% of US stocks

Growth & margins
Revenue growth (YoY)
−41.8%

Higher than 7% of US stocks

Earnings growth (YoY)
—
Gross margin
50.0%

Higher than 62% of US stocks

Operating margin
−7450.3%

Higher than 2% of US stocks

Net margin
47.3%

Higher than 96% of US stocks

Returns & dividend
Return on equity
−49.1%

Higher than 22% of US stocks

Return on assets
−25.7%

Higher than 16% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Quantum-Si, Inc. (QSI) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Quantum-Si, Inc. has a market value of $267.0M and an enterprise value of $158.6M.

  • Revenue in the twelve months to 30 June 2026: $1.6M. The latest quarter shrank 41.8% year on year.

  • Net income over the same four quarters: −$98.5M, a −6138.3% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.46.

  • Free cash flow in the twelve months to 30 June 2026: −$93.7M.

  • Shares outstanding: 218.9M.

  • Trailing P/E: −2.4×; forward P/E: −3.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Quantum-Si, Inc. employs 145 people — $11K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 7 Oct 2026

Data provided by Twelve Data

Peers

QSI vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
QSIQuantum-Si, Inc.$267.0M
36
LABStandard BioTools, Inc.$261.5M
26
INFUInfuSystem Holdings, Inc.$267.1M
100
TLSITriSalus Life Sciences, Inc.$247.0M
32
TMCITreace Medical Concepts, Inc.$246.9M
53
MOBIMobia Medical, Inc.$283.2M
2
ELMDElectromed, Inc.$231.9M
92

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Quantum-Si, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest QSI news & analysis

3 Biotech Stocks Put Traders Are Targeting Today

Schaeffers Research · 1 Oct 2026neutral

Quantum-Si Inc, along with Nektar Therapeutics and Pacific Biosciences, is drawing elevated options activity today as biotech stocks make volatile moves. Schaeffers Research identified these companies as targets of active put traders.

Why it matters — The report highlights notable options-market interest in QSI, which QSI watchers may view as an indicator of trader attention on the stock amid biotech sector volatility.

Quantum-Si Presents Interim Proteus™ Data at World HUPO 2026 Demonstrating a Significant Step Change in Performance Compared to Platinum® Pro

GlobeNewsWire · 29 Sept 2026positive

Quantum-Si announced interim development results at the World HUPO 2026 conference comparing its next-generation Proteus platform with its commercially available Platinum Pro instrument, describing the data as demonstrating a significant step change in performance.

Why it matters — QSI watchers would care because the interim data suggests meaningful performance improvement for the company's next-generation Proteus platform relative to its current commercial instrument.

Quantum-Si Announces Detection of 18 Amino Acids Using a Developmental Sequencing Kit on Proteus™

GlobeNewsWire · 15 Sept 2026positive

Quantum-Si announced that it has demonstrated sequencing with detection of 18 amino acids using a developmental kit run on integrated Proteus instruments. The announcement was made via GlobeNewsWire and highlights progress in its single-molecule protein sequencing technology.

Why it matters — QSI watchers would care because demonstrating detection of 18 amino acids on integrated Proteus instruments signals technical advancement in the company's protein sequencing platform.

Quantum-Si Expands Proteus™ Roadshow with Additional U.S. and European Cities

GlobeNewsWire · 9 Sept 2026positive

Quantum-Si announced an expansion of its Proteus roadshow with additional U.S. and European cities. The roadshow is designed to accelerate market education on the Proteus platform and its applications for protein sequencing.

Why it matters — A QSI watcher would care because the expanded roadshow is intended to raise market awareness and education around the company's Proteus protein-sequencing platform.

Quantum-Si to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

GlobeNewsWire · 18 Aug 2026neutral

Quantum-Si, Inc. announced on August 18, 2026, that it will participate in the H.C. Wainwright 28th Annual Global Investment Conference. The proteomics technology company made the announcement via GlobeNewsWire from its Branford, Connecticut headquarters.

Why it matters — Participation in a major investment conference gives Quantum-Si an opportunity to present its single-molecule protein sequencing technology to investors and financial community members.

FAQ

Frequently asked questions about QSI stock

What is the QSI stock price forecast for 2026-2027?

The 3 Wall Street analysts covering Quantum-Si, Inc. have a median 12-month price target of $1.9, with estimates ranging from $1 to $3.95. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is QSI stock a buy right now?

Of the 3 analysts covering Quantum-Si, Inc., 2 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Quantum-Si, Inc. 36 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank QSI?

As at 8 Oct 2026, Quantum-Si, Inc. ranks 36 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (79 of 100).

Will QSI stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +55.7% from the last close, and Ticker Nerd's factor model ranks Quantum-Si, Inc. 36 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the QSI stock forecast for 2030?

No analyst covering Quantum-Si, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for QSI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1 to $3.95 over the next 12 months.

How has QSI stock performed over the past year?

Quantum-Si, Inc. returned -31.1% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Quantum-Si, Inc. do?

Quantum-Si Incorporated Class A Common Stock represents ownership in Quantum-Si Incorporated, a life sciences company focused on proteomics and single-molecule protein analysis. Quantum-Si develops benchtop instrumentation, consumables, and software designed to support next-generation protein sequencing and automated protein data interpretation.

What is the latest news on QSI?

The most recent item we track (Schaeffers Research, 1 Oct 2026): "3 Biotech Stocks Put Traders Are Targeting Today". Quantum-Si Inc, along with Nektar Therapeutics and Pacific Biosciences, is drawing elevated options activity today as biotech stocks make volatile moves. Schaeffers Research identified these companies as targets of active put traders.

Company

About Quantum-Si, Inc.

Quantum-Si Incorporated Class A Common Stock represents ownership in Quantum-Si Incorporated, a life sciences company focused on proteomics and single-molecule protein analysis. Quantum-Si develops benchtop instrumentation, consumables, and software designed to support next-generation protein sequencing and automated protein data interpretation. Its current product set includes the Platinum and Platinum Pro instruments, library preparation kits, sequencing kits, and analysis software used in protein identification, protein variant detection, biomarker research, antibody characterization, and post-translational modification analysis. The company serves research laboratories and scientific organizations that need tools for detailed protein-level investigation. Quantum-Si Incorporated Class A Common Stock reflects a market position tied to specialized biotechnology research tools and the broader demand for advanced protein analysis technologies in the life sciences sector.

CEO Mr. Jeffrey Alan Hawkins · 145 employees · United States · https://www.quantum-si.com